Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTUW | ISIN: US6960775020 | Ticker-Symbol: PTN
Stuttgart
25.06.25 | 20:47
0,143 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALATIN TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
PALATIN TECHNOLOGIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1160,15422:52

Aktuelle News zur PALATIN TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.PALATIN TECHNOLOGIES INC - 8-K, Current Report70
PALATIN TECHNOLOGIES Aktie jetzt für 0€ handeln
14.05.PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report96
14.05.Palatin Technologies Q1 Net Loss Narrows On Lower Expenses852WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin...
► Artikel lesen
14.05.Palatin Technologies GAAP EPS of -$0.1836
14.05.Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update273Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM EST CRANBURY, N.J., May 14, 2025...
► Artikel lesen
10.05.Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025816WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT), a biopharmaceutical company advancing melanocortin-based therapies, shared new preclinical findings at the 2025 ARVO Annual Meeting....
► Artikel lesen
09.05.Palatin enthüllt potenzielle Behandlungen für diabetische Retinopathie64
09.05.Palatin reveals potential diabetic retinopathy treatments10
09.05.Palatin Technologies, Inc.: Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025393Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654...
► Artikel lesen
09.05.Palatin Technologies, Inc.: Palatin Technologies Announces Closing of Reduced Public Offering1.072Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"),...
► Artikel lesen
08.05.PALATIN TECHNOLOGIES INC - 8-K, Current Report19
08.05.Palatin Technologies, Inc.: Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025126Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically...
► Artikel lesen
08.05.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025709The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE...
► Artikel lesen
08.05.Palatin Technologies, Inc.: Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice411The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the...
► Artikel lesen
07.05.Palatin Technologies droht Delisting von der NYSE American wegen niedrigem Aktienkurs66
07.05.Palatin Technologies faces delisting from NYSE American due to low stock price6
07.05.Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development457WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) Wednesday announced that it anticipates closing its previously disclosed public offering on May 8, 2025. The offering includes $11.5 million...
► Artikel lesen
07.05.Palatin Prices $11.5 Mln Public Offering531WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), a biopharmaceutical firm focused on melanocortin-based treatments, has priced a public offering totaling approximately $11.5 million....
► Artikel lesen
07.05.XFRA PTN: AUSSETZUNG/SUSPENSION422DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPALATIN TECHS DL-...
► Artikel lesen
07.05.Palatin expects $11.5M financing to cure NYSE American delisting notice21
Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
5,1,85